178 related articles for article (PubMed ID: 29254937)
1. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.
Korde LA; Doody DR; Hsu L; Porter PL; Malone KE
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):165-173. PubMed ID: 29254937
[No Abstract] [Full Text] [Related]
2. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
7. Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer.
Ethier JL; Prince RM; Amir E
Curr Oncol Rep; 2017 Mar; 19(3):15. PubMed ID: 28251493
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and breast cancer prevention.
Chlebowski RT; Col N
Anticancer Agents Med Chem; 2012 Feb; 12(2):144-50. PubMed ID: 21864227
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Lipton A; Chapman JW; Leitzel K; Garg A; Pritchard KI; Ingle JN; Budd GT; Ellis MJ; Sledge GW; Rabaglio M; Han L; Elliott CR; Shepherd LE; Goss PE; Ali SM
Cancer; 2017 Jul; 123(13):2444-2451. PubMed ID: 28464211
[TBL] [Abstract][Full Text] [Related]
11. Role of Bisphosphonates in Breast Cancer Therapy.
Goldvaser H; Amir E
Curr Treat Options Oncol; 2019 Mar; 20(4):26. PubMed ID: 30874905
[TBL] [Abstract][Full Text] [Related]
12. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
[TBL] [Abstract][Full Text] [Related]
13. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.
Mauri D; Valachis A; Polyzos NP; Tsali L; Mavroudis D; Georgoulias V; Casazza G
J Natl Compr Canc Netw; 2010 Mar; 8(3):279-86. PubMed ID: 20202461
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Nahleh Z; Abrams J; Bhargaval A; Nirmal K; Graff JJ
Clin Breast Cancer; 2010 Dec; 10(6):459-64. PubMed ID: 21147689
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
17. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
Fick EM; Katalinic A; Waldmann A
Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG;
Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
